Q2 FY2026 EarningsQ2 FY26 results beat consensus on bottom-line metrics despite a slight revenue miss: revenue $10.1M vs. $10.5M expected, and GAAP EPS -$1.23 vs. -$1.93 expected. The narrower-than-expected net loss was driven by significant interest income ($9.3M) from a strengthened cash position of $1.02B and disciplined G&A spending. Management initiated Phase 3 ZENITH AD trials in July, with R&D expenses rising 31% YoY to support registrational activities.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Nektar Therap(NKTR) the Revenue is 10.13 M (-9.34%), Miss estimate;the EBIT is -42.34 M (-16.87%), Beat estimate;the EPS is -1.23 (+58.31%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueMiss expectations
0.01B9.34%
0.01B6.30%
-0.00B3.04%
EBITExceed expectations
-0.04B16.87%
-0.05B51.64%
+0.01B34.77%
EPSExceed expectations
-1.2358.31%
-1.932934.48%
+0.702923.83%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf